Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours

Trial Profile

Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs ONCOS 102 (Primary) ; ONCOS 102 (Primary) ; Cyclophosphamide
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Oncos Therapeutics
  • Most Recent Events

    • 09 Jun 2016 Results published in Targovax media release.
    • 05 Nov 2015 According to an Oncos media release, results from this trial will be presented at the SITC 2015 - an annual event of The Society for Immunotherapy of Cancer.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top